Kewaunee Scientific Corporation · NASDAQ:KEQU

Kewaunee Scientific — Investor Presentation (2019)

23 slides from Kewaunee Scientific's investor presentation, 2019

  1. Slide 1: Kewaunee Scientific Corporation

    Kewaunee Scientific Corporation NASDAQ: KEQU encouraging new discovery…Worldwide 1

  2. Slide 2: Special Note Regarding Forward-Looking Statements

    Special Note Regarding Forward-Looking Statements Certain statements in this document constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements other than statements of historical fact included in this docume

  3. Slide 3: Agenda

    Agenda • Fiscal Year 2019 Review • Fiscal Year 2020 Q1 Results • Outlook • Q&A Kewaunee Scientific Corporation | NASDAQ: KEQU 3

  4. Slide 4: Fiscal Year 2019 Review

    Fiscal Year 2019 Review Kewaunee Scientific Corporation | NASDAQ: KEQU 4

  5. Slide 5: Fiscal Year 2019 Financial Review

    Fiscal Year 2019 Financial Review Sales ($m) $158 Gross Profit ($m) $160 $32 $150 $147 $30 $27 $24 $25 $139 $140 $129 $20 $130 $120 $10 $110 $100 $- 2016 2017 2018 2019 2016 2017 2018 2019 Pretax Earnings ($m) Diluted EPS $10 $1.90 $10 $2.00 $1.66 $7 $1.42 $1.50 $6 $5 $1.00 $0.55 $2 $0.50 $- $- 2016

  6. Slide 6: Kewaunee Domestic Operating Segment

    Fiscal Year 2019 Financial Review Designs, manufactures, and installs laboratory, healthcare, and technical furniture products Sold through dealers, and distribution channels as well as directly to the end-user Products manufactured in Statesville, North Carolina Kewaunee Domestic Operating Segment

  7. Slide 7: Domestic Operating Segment Sales

    Fiscal Year 2019 Financial Review Domestic Operating Segment Sales ($Millions) $120  Up year-over-year as $117 $115 activity in the $115 $113 marketplace remained $110 favorable.  Order mix across dealer, $105 $103 direct and distribution channels remained $100 2016 2017 2018 2019 consistent over

  8. Slide 8: Domestic Operating Segment Quarterly Sales

    Fiscal Year 2019 Financial Review Domestic Operating Segment Quarterly Sales ($Millions) $40  Timing of orders did not $36 $35 support effective loading of facilities over the $31 $30 balance of the fiscal year resulting in unfavorable $25 $25 $25 labor and overhead cost and productivity. $20 Q1-FY

  9. Slide 9: Domestic Segment Raw Material Impacts

    Fiscal Year 2019 Financial Review Domestic Operating Segment  Primary raw materials impacts: • Cold rolled steel and Stainless steel, ~ 12% cost increase • Epoxy resin raw material, ~40% cost increase Kewaunee Scientific Corporation | NASDAQ: KEQU 9

  10. Slide 10: Kewaunee International Operating Segment

    Fiscal Year 2019 Financial Review Turn-key provider of total laboratory solution – design, manufacture, installation, maintenance Sold principally direct to end-users Products for international markets manufactured in Bangalore India and sourced from Statesville NC facility Kewaunee International Op

  11. Slide 11: International Operating Segment Annual Sales

    Fiscal Year 2019 Financial Review International Operating Segment Annual Sales ($Millions) $45 $43  Sales down due to lack $40 of large Middle East $35 order ($18M delivered $30 in FY 2018) $30 $26  Sales impacted by year- $25 $25 over-year FX impact of $20 INR vs. USD (~12%). FY2016 FY2017 FY2018

  12. Slide 12: Corporate Costs

    Fiscal Year 2019 Financial Review Corporate Costs  $75M market cap threshold, required preparation for possible loss of “smaller reporting company” scaled compliance requirements  Tax Reform Implementation  Accounting changes (revenue recognition, inventory valuation, lease accounting, etc.)  On

  13. Slide 13: Fiscal Year 2020 Q1 Performance

    Fiscal Year 2020 Q1 Performance Kewaunee Scientific Corporation | NASDAQ: KEQU 13

  14. Slide 14: 2020 First Quarter

    Fiscal Year 2020 First Quarter $50 Sales ($m) Gross Profit ($m) $45 $42.2 $10 $39.3 $7.6 $6.9 $40 $35 $5 $30 $25 $- FY 2019 Q1 FY 2020 Q1 FY 2019 Q1 FY 2020 Q1 $3 Pretax Earnings ($m) $1.00 Diluted EPS $2 $1.9 $0.53 $0.50 $1 $0.7 $0.17 $- $- FY 2019 Q1 FY 2020 Q1 FY 2019 Q1 FY 2020 Q1 Kewaunee Scien

  15. Slide 15: Outlook

    Outlook Kewaunee Scientific Corporation | NASDAQ: KEQU 15

  16. Slide 16: Our Vision

    Our Vision “To be the global supplier of choice with customers in the lab furniture and infrastructure markets.” Kewaunee Scientific Corporation | NASDAQ: KEQU 16

  17. Slide 17: Our Core Values

    Our Core Values Associates, our Foundation – Each and every Kewaunee Associate matters and we invest in them by encouraging development and growth through feedback, mentorship, reward, accountability, and continuing education. Safety and Quality in Everything - If we choose to do something, we are g

  18. Slide 18: Kewaunee Management Team

    Kewaunee Management Team Donald T. Gardner, III Michael G. Rok Lisa L. Ryan Kurt P. Rindoks Elizabeth D. Phillips Ryan S. Noble B. Sathyamurthy Kewaunee Scientific Corporation | NASDAQ: KEQU 18

  19. Slide 19: Active in Multiple Sectors

    HEALTH • Market includes life sciences, pharmaceutical, bio- technology and healthcare customers • Macro population and aging trends support continued investment in health related initiatives requiring laboratories INDUSTRIAL • Market includes chemicals, petroleum, manufacturing Active in and aerosp

  20. Slide 20: Continued Global Growth Opportunity

    Continued Global Growth Opportunity: 2020 Lab Furniture and • According to the SEFA Enclosure Global Market Laboratory and Furniture 5% Market Report, the overall market for laboratory furniture and enclosures is forecasted to 27% $ 1.6B grow at a 5 year compound Market 41% Opportunity annual growth

  21. Slide 21: Outlook: Order Backlog

    Outlook Order Backlog (millions) $130 $114 $116 $110 $101 $102 $101 $90 $70 $50 2016 2017 2018 2019 Q1-2020 Focused on increasing backlog through continued focus on winning with our channel partners. Kewaunee is positioned well to benefit from the projected growth in research and development spendin

  22. Slide 22: Outlook: Near and Longer Term Priorities

    Outlook 2018 Lab Furniture and Enclosure Global Market* • Near Term Priorities:  Operate consistently at higher levels  Do what we do well  Strengthen our balance sheet • Longer Term Priorities:  Expand product portfolio  Penetrate underserved markets  Evaluate outside opportunities Kewaunee S

  23. Slide 23: Thank You

    Thank You Kewaunee Scientific Corporation | NASDAQ: KEQU 23

Kewaunee Scientific — Investor Presentation (2019) on 6ix